Eintrag weiter verarbeiten

Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Immunity, Inflammation and Disease
Personen und Körperschaften: Ngu, Loveline N., Nji, Nadesh N., Ambada, Georgia, Ngoh, Apeh A., Njambe Priso, Ghislain D., Tchadji, Jules C., Lissom, Abel, Magagoum, Suzanne H., Sake, Carol N., Tchouangueu, Thibau F., Chukwuma, George O., Okoli, Arinze S., Sagnia, Bertrand, Chukwuanukwu, Rebecca, Tebit, Denis M., Esimone, Charles O., Waffo, Alain B., Park, Chae G., Überla, Klaus, Nchinda, Godwin W.
In: Immunity, Inflammation and Disease, 6, 2018, 1, S. 163-175
Format: E-Article
Sprache: Englisch
veröffentlicht:
Wiley
Schlagwörter:
author_facet Ngu, Loveline N.
Nji, Nadesh N.
Ambada, Georgia
Ngoh, Apeh A.
Njambe Priso, Ghislain D.
Tchadji, Jules C.
Lissom, Abel
Magagoum, Suzanne H.
Sake, Carol N.
Tchouangueu, Thibau F.
Chukwuma, George O.
Okoli, Arinze S.
Sagnia, Bertrand
Chukwuanukwu, Rebecca
Tebit, Denis M.
Esimone, Charles O.
Waffo, Alain B.
Park, Chae G.
Überla, Klaus
Nchinda, Godwin W.
Ngu, Loveline N.
Nji, Nadesh N.
Ambada, Georgia
Ngoh, Apeh A.
Njambe Priso, Ghislain D.
Tchadji, Jules C.
Lissom, Abel
Magagoum, Suzanne H.
Sake, Carol N.
Tchouangueu, Thibau F.
Chukwuma, George O.
Okoli, Arinze S.
Sagnia, Bertrand
Chukwuanukwu, Rebecca
Tebit, Denis M.
Esimone, Charles O.
Waffo, Alain B.
Park, Chae G.
Überla, Klaus
Nchinda, Godwin W.
author Ngu, Loveline N.
Nji, Nadesh N.
Ambada, Georgia
Ngoh, Apeh A.
Njambe Priso, Ghislain D.
Tchadji, Jules C.
Lissom, Abel
Magagoum, Suzanne H.
Sake, Carol N.
Tchouangueu, Thibau F.
Chukwuma, George O.
Okoli, Arinze S.
Sagnia, Bertrand
Chukwuanukwu, Rebecca
Tebit, Denis M.
Esimone, Charles O.
Waffo, Alain B.
Park, Chae G.
Überla, Klaus
Nchinda, Godwin W.
spellingShingle Ngu, Loveline N.
Nji, Nadesh N.
Ambada, Georgia
Ngoh, Apeh A.
Njambe Priso, Ghislain D.
Tchadji, Jules C.
Lissom, Abel
Magagoum, Suzanne H.
Sake, Carol N.
Tchouangueu, Thibau F.
Chukwuma, George O.
Okoli, Arinze S.
Sagnia, Bertrand
Chukwuanukwu, Rebecca
Tebit, Denis M.
Esimone, Charles O.
Waffo, Alain B.
Park, Chae G.
Überla, Klaus
Nchinda, Godwin W.
Immunity, Inflammation and Disease
Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
Immunology
Immunology and Allergy
author_sort ngu, loveline n.
spelling Ngu, Loveline N. Nji, Nadesh N. Ambada, Georgia Ngoh, Apeh A. Njambe Priso, Ghislain D. Tchadji, Jules C. Lissom, Abel Magagoum, Suzanne H. Sake, Carol N. Tchouangueu, Thibau F. Chukwuma, George O. Okoli, Arinze S. Sagnia, Bertrand Chukwuanukwu, Rebecca Tebit, Denis M. Esimone, Charles O. Waffo, Alain B. Park, Chae G. Überla, Klaus Nchinda, Godwin W. 2050-4527 2050-4527 Wiley Immunology Immunology and Allergy http://dx.doi.org/10.1002/iid3.209 <jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Recombinant Newcastle Disease virus (rNDV) vectored vaccines are safe mucosal applicable vaccines with intrinsic immune‐modulatory properties for the induction of efficient immunity. Like all viral vectored vaccines repeated inoculation via mucosal routes invariably results to immunity against viral vaccine vectors. To obviate immunity against viral vaccine vectors and improve the ability of rNDV vectored vaccines in inducing T cell immunity in murine air way we have directed dendritic cell targeted HIV‐1 gag protein (DEC‐Gag) vaccine; for the induction of helper CD4<jats:sup>+</jats:sup> T cells to a Recombinant Newcastle disease virus expressing codon optimized HIV‐1 Gag P55 (rNDV‐L‐Gag) vaccine.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We do so through successive administration of anti‐DEC205‐gagP24 protein plus polyICLC (DEC‐Gag) vaccine and rNDV‐L‐Gag. First strong gag specific helper CD4<jats:sup>+</jats:sup> T cells are induced in mice by selected targeting of anti‐DEC205‐gagP24 protein vaccine to dendritic cells (DC) <jats:italic>in situ</jats:italic> together with polyICLC as adjuvant. This targeting helped T cell immunity develop to a subsequent rNDV‐L‐Gag vaccine and improved both systemic and mucosal gag specific immunity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This sequential DEC‐Gag vaccine prime followed by an rNDV‐L‐gag boost results to improved viral vectored immunization in murine airway, including mobilization of protective CD8<jats:sup>+</jats:sup> T cells to a pathogenic virus infection site.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Thus, complementary prime boost vaccination, in which prime and boost favor distinct types of T cell immunity, improves viral vectored immunization, including mobilization of protective CD8<jats:sup>+</jats:sup>T cells to a pathogenic virus infection site such as the murine airway.</jats:p></jats:sec> Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8<sup>+</sup> T cells Immunity, Inflammation and Disease
doi_str_mv 10.1002/iid3.209
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9paWQzLjIwOQ
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9paWQzLjIwOQ
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
imprint Wiley, 2018
imprint_str_mv Wiley, 2018
issn 2050-4527
issn_str_mv 2050-4527
language English
mega_collection Wiley (CrossRef)
match_str ngu2018dendriticcelltargetedhiv1gagproteinvaccineprovideshelptoarecombinantnewcastlediseasevirusvectoredvaccineincludingmobilizationofprotectivecd8tcells
publishDateSort 2018
publisher Wiley
recordtype ai
record_format ai
series Immunity, Inflammation and Disease
source_id 49
title Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_unstemmed Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_full Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_fullStr Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_full_unstemmed Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_short Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_sort dendritic cell targeted hiv‐1 gag protein vaccine provides help to a recombinant newcastle disease virus vectored vaccine including mobilization of protective cd8<sup>+</sup> t cells
topic Immunology
Immunology and Allergy
url http://dx.doi.org/10.1002/iid3.209
publishDate 2018
physical 163-175
description <jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Recombinant Newcastle Disease virus (rNDV) vectored vaccines are safe mucosal applicable vaccines with intrinsic immune‐modulatory properties for the induction of efficient immunity. Like all viral vectored vaccines repeated inoculation via mucosal routes invariably results to immunity against viral vaccine vectors. To obviate immunity against viral vaccine vectors and improve the ability of rNDV vectored vaccines in inducing T cell immunity in murine air way we have directed dendritic cell targeted HIV‐1 gag protein (DEC‐Gag) vaccine; for the induction of helper CD4<jats:sup>+</jats:sup> T cells to a Recombinant Newcastle disease virus expressing codon optimized HIV‐1 Gag P55 (rNDV‐L‐Gag) vaccine.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We do so through successive administration of anti‐DEC205‐gagP24 protein plus polyICLC (DEC‐Gag) vaccine and rNDV‐L‐Gag. First strong gag specific helper CD4<jats:sup>+</jats:sup> T cells are induced in mice by selected targeting of anti‐DEC205‐gagP24 protein vaccine to dendritic cells (DC) <jats:italic>in situ</jats:italic> together with polyICLC as adjuvant. This targeting helped T cell immunity develop to a subsequent rNDV‐L‐Gag vaccine and improved both systemic and mucosal gag specific immunity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This sequential DEC‐Gag vaccine prime followed by an rNDV‐L‐gag boost results to improved viral vectored immunization in murine airway, including mobilization of protective CD8<jats:sup>+</jats:sup> T cells to a pathogenic virus infection site.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Thus, complementary prime boost vaccination, in which prime and boost favor distinct types of T cell immunity, improves viral vectored immunization, including mobilization of protective CD8<jats:sup>+</jats:sup>T cells to a pathogenic virus infection site such as the murine airway.</jats:p></jats:sec>
container_issue 1
container_start_page 163
container_title Immunity, Inflammation and Disease
container_volume 6
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792340805097095168
geogr_code not assigned
last_indexed 2024-03-01T16:09:51.498Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Dendritic+cell+targeted+HIV%E2%80%901+gag+protein+vaccine+provides+help+to+a+recombinant+Newcastle+disease+virus+vectored+vaccine+including+mobilization+of+protective+CD8%2B+T+cells&rft.date=2018-03-01&genre=article&issn=2050-4527&volume=6&issue=1&spage=163&epage=175&pages=163-175&jtitle=Immunity%2C+Inflammation+and+Disease&atitle=Dendritic+cell+targeted+HIV%E2%80%901+gag+protein+vaccine+provides+help+to+a+recombinant+Newcastle+disease+virus+vectored+vaccine+including+mobilization+of+protective+CD8%3Csup%3E%2B%3C%2Fsup%3E+T+cells&aulast=Nchinda&aufirst=Godwin+W.&rft_id=info%3Adoi%2F10.1002%2Fiid3.209&rft.language%5B0%5D=eng
SOLR
_version_ 1792340805097095168
author Ngu, Loveline N., Nji, Nadesh N., Ambada, Georgia, Ngoh, Apeh A., Njambe Priso, Ghislain D., Tchadji, Jules C., Lissom, Abel, Magagoum, Suzanne H., Sake, Carol N., Tchouangueu, Thibau F., Chukwuma, George O., Okoli, Arinze S., Sagnia, Bertrand, Chukwuanukwu, Rebecca, Tebit, Denis M., Esimone, Charles O., Waffo, Alain B., Park, Chae G., Überla, Klaus, Nchinda, Godwin W.
author_facet Ngu, Loveline N., Nji, Nadesh N., Ambada, Georgia, Ngoh, Apeh A., Njambe Priso, Ghislain D., Tchadji, Jules C., Lissom, Abel, Magagoum, Suzanne H., Sake, Carol N., Tchouangueu, Thibau F., Chukwuma, George O., Okoli, Arinze S., Sagnia, Bertrand, Chukwuanukwu, Rebecca, Tebit, Denis M., Esimone, Charles O., Waffo, Alain B., Park, Chae G., Überla, Klaus, Nchinda, Godwin W., Ngu, Loveline N., Nji, Nadesh N., Ambada, Georgia, Ngoh, Apeh A., Njambe Priso, Ghislain D., Tchadji, Jules C., Lissom, Abel, Magagoum, Suzanne H., Sake, Carol N., Tchouangueu, Thibau F., Chukwuma, George O., Okoli, Arinze S., Sagnia, Bertrand, Chukwuanukwu, Rebecca, Tebit, Denis M., Esimone, Charles O., Waffo, Alain B., Park, Chae G., Überla, Klaus, Nchinda, Godwin W.
author_sort ngu, loveline n.
container_issue 1
container_start_page 163
container_title Immunity, Inflammation and Disease
container_volume 6
description <jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Recombinant Newcastle Disease virus (rNDV) vectored vaccines are safe mucosal applicable vaccines with intrinsic immune‐modulatory properties for the induction of efficient immunity. Like all viral vectored vaccines repeated inoculation via mucosal routes invariably results to immunity against viral vaccine vectors. To obviate immunity against viral vaccine vectors and improve the ability of rNDV vectored vaccines in inducing T cell immunity in murine air way we have directed dendritic cell targeted HIV‐1 gag protein (DEC‐Gag) vaccine; for the induction of helper CD4<jats:sup>+</jats:sup> T cells to a Recombinant Newcastle disease virus expressing codon optimized HIV‐1 Gag P55 (rNDV‐L‐Gag) vaccine.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We do so through successive administration of anti‐DEC205‐gagP24 protein plus polyICLC (DEC‐Gag) vaccine and rNDV‐L‐Gag. First strong gag specific helper CD4<jats:sup>+</jats:sup> T cells are induced in mice by selected targeting of anti‐DEC205‐gagP24 protein vaccine to dendritic cells (DC) <jats:italic>in situ</jats:italic> together with polyICLC as adjuvant. This targeting helped T cell immunity develop to a subsequent rNDV‐L‐Gag vaccine and improved both systemic and mucosal gag specific immunity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This sequential DEC‐Gag vaccine prime followed by an rNDV‐L‐gag boost results to improved viral vectored immunization in murine airway, including mobilization of protective CD8<jats:sup>+</jats:sup> T cells to a pathogenic virus infection site.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Thus, complementary prime boost vaccination, in which prime and boost favor distinct types of T cell immunity, improves viral vectored immunization, including mobilization of protective CD8<jats:sup>+</jats:sup>T cells to a pathogenic virus infection site such as the murine airway.</jats:p></jats:sec>
doi_str_mv 10.1002/iid3.209
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9paWQzLjIwOQ
imprint Wiley, 2018
imprint_str_mv Wiley, 2018
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2
issn 2050-4527
issn_str_mv 2050-4527
language English
last_indexed 2024-03-01T16:09:51.498Z
match_str ngu2018dendriticcelltargetedhiv1gagproteinvaccineprovideshelptoarecombinantnewcastlediseasevirusvectoredvaccineincludingmobilizationofprotectivecd8tcells
mega_collection Wiley (CrossRef)
physical 163-175
publishDate 2018
publishDateSort 2018
publisher Wiley
record_format ai
recordtype ai
series Immunity, Inflammation and Disease
source_id 49
spelling Ngu, Loveline N. Nji, Nadesh N. Ambada, Georgia Ngoh, Apeh A. Njambe Priso, Ghislain D. Tchadji, Jules C. Lissom, Abel Magagoum, Suzanne H. Sake, Carol N. Tchouangueu, Thibau F. Chukwuma, George O. Okoli, Arinze S. Sagnia, Bertrand Chukwuanukwu, Rebecca Tebit, Denis M. Esimone, Charles O. Waffo, Alain B. Park, Chae G. Überla, Klaus Nchinda, Godwin W. 2050-4527 2050-4527 Wiley Immunology Immunology and Allergy http://dx.doi.org/10.1002/iid3.209 <jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Recombinant Newcastle Disease virus (rNDV) vectored vaccines are safe mucosal applicable vaccines with intrinsic immune‐modulatory properties for the induction of efficient immunity. Like all viral vectored vaccines repeated inoculation via mucosal routes invariably results to immunity against viral vaccine vectors. To obviate immunity against viral vaccine vectors and improve the ability of rNDV vectored vaccines in inducing T cell immunity in murine air way we have directed dendritic cell targeted HIV‐1 gag protein (DEC‐Gag) vaccine; for the induction of helper CD4<jats:sup>+</jats:sup> T cells to a Recombinant Newcastle disease virus expressing codon optimized HIV‐1 Gag P55 (rNDV‐L‐Gag) vaccine.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We do so through successive administration of anti‐DEC205‐gagP24 protein plus polyICLC (DEC‐Gag) vaccine and rNDV‐L‐Gag. First strong gag specific helper CD4<jats:sup>+</jats:sup> T cells are induced in mice by selected targeting of anti‐DEC205‐gagP24 protein vaccine to dendritic cells (DC) <jats:italic>in situ</jats:italic> together with polyICLC as adjuvant. This targeting helped T cell immunity develop to a subsequent rNDV‐L‐Gag vaccine and improved both systemic and mucosal gag specific immunity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This sequential DEC‐Gag vaccine prime followed by an rNDV‐L‐gag boost results to improved viral vectored immunization in murine airway, including mobilization of protective CD8<jats:sup>+</jats:sup> T cells to a pathogenic virus infection site.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Thus, complementary prime boost vaccination, in which prime and boost favor distinct types of T cell immunity, improves viral vectored immunization, including mobilization of protective CD8<jats:sup>+</jats:sup>T cells to a pathogenic virus infection site such as the murine airway.</jats:p></jats:sec> Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8<sup>+</sup> T cells Immunity, Inflammation and Disease
spellingShingle Ngu, Loveline N., Nji, Nadesh N., Ambada, Georgia, Ngoh, Apeh A., Njambe Priso, Ghislain D., Tchadji, Jules C., Lissom, Abel, Magagoum, Suzanne H., Sake, Carol N., Tchouangueu, Thibau F., Chukwuma, George O., Okoli, Arinze S., Sagnia, Bertrand, Chukwuanukwu, Rebecca, Tebit, Denis M., Esimone, Charles O., Waffo, Alain B., Park, Chae G., Überla, Klaus, Nchinda, Godwin W., Immunity, Inflammation and Disease, Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells, Immunology, Immunology and Allergy
title Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_full Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_fullStr Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_full_unstemmed Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_short Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
title_sort dendritic cell targeted hiv‐1 gag protein vaccine provides help to a recombinant newcastle disease virus vectored vaccine including mobilization of protective cd8<sup>+</sup> t cells
title_unstemmed Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells
topic Immunology, Immunology and Allergy
url http://dx.doi.org/10.1002/iid3.209